Literature DB >> 28936889

T2 relaxometry mapping in demonstrating layered uterine architecture: parameter optimization and utility in endometrial carcinoma and adenomyosis: a feasibility study.

Adarsh Ghosh1, Tulika Singh1, Rashmi Bagga2, Radhika Srinivasan3, Veenu Singla1, Niranjan Khandelwal1.   

Abstract

OBJECTIVE: We evaluate the feasibility of T2 relaxometry mapping of the uterus and demonstrate its diagnostic utility in endometrial carcinoma and adenomyosis and discuss the optimum imaging parameters as used in our institute.
METHODS: Institute review board approval was obtained and multispin echo (MSE) imaging of the pelvis was done with variable time to echo in three patients, two with endometrial carcinoma and one with adenomyosis. T2 parametric maps and curves were plotted and the T2 times of the diseased endometrium, superficial and deep myometrium were established.
RESULTS: T2 mapping of the uterus is feasible and demonstrated the four-layered uterine architecture with T2 times of the diseased endometrium, inner myometrium and the outer myometrium being determined. The fourth myometrial layer was demonstrated in all the three cases on the parametric maps. The two cases with endometrial carcinoma had thinning and irregularity of the myometrial fourth layer which helped in predicting superficial myometrium invasion. Thickening of the fourth myometrial layer was demonstrated in the case with adenomyosis, which we believe might be a new imaging finding of adenomyosis.
CONCLUSION: Thinning and irregularity of the myometrial fourth layer in cases of endometrial malignancy might help in identification of superficial myoinvasion-this might be a new imaging armamentarium in nulliparous females where uterine preservation might be a consideration. The T2 relaxation times of the myometrium and endometrium described here will help optimize the time to echo for the acquisition of MSE for relaxometry of the female pelvis. Advances in knowledge: Thinning and irregularity of the fourth myometrial layer helps in the identification of superficial myometrial invasion with a greater confidence and helps triage patients for uterine preservation when necessary. T2 relaxometry might be undertaken in those nulliparous women with endometrial carcinoma in whom demonstration of no myometrial invasion will make them candidates for uterine preservation. Thickening of the fourth myometrial layer in adenomyosis requires further evaluation in a larger cohort of patients as an additional imaging finding. T2 relaxation times of endometrial carcinoma is different from the normal endometrium in the three cases imaged, thus, further studies evaluating the T2 values in a larger cohort might help in differentiating diseased from the healthy endometrium. T2 time of the pelvic tissue described in the study will help select the time to echoes for MSE imaging of the female pelvis in further studies.

Entities:  

Mesh:

Year:  2017        PMID: 28936889      PMCID: PMC5966209          DOI: 10.1259/bjr.20170377

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  10 in total

1.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology.

Authors:  J L Benedet; H Bender; H Jones; H Y Ngan; S Pecorelli
Journal:  Int J Gynaecol Obstet       Date:  2000-08       Impact factor: 3.561

2.  Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.

Authors:  T Kaku; H Yoshikawa; H Tsuda; A Sakamoto; M Fukunaga; Y Kuwabara; M Hataeg; S Kodama; K Kuzuya; S Sato; T Nishimura; M Hiura; H Nakano; T Iwasaka; K Miyazaki; T Kamura
Journal:  Cancer Lett       Date:  2001-06-10       Impact factor: 8.679

Review 3.  Principles, techniques, and applications of T2*-based MR imaging and its special applications.

Authors:  Govind B Chavhan; Paul S Babyn; Bejoy Thomas; Manohar M Shroff; E Mark Haacke
Journal:  Radiographics       Date:  2009 Sep-Oct       Impact factor: 5.333

4.  T2* relaxometry mapping of the uterine zones.

Authors:  Izumi Imaoka; Takayuki Nakatsuka; Tetsuro Araki; Takashi Katsube; Masahiro Okada; Seishi Kumano; Kazunari Ishii; Ryuichiro Ashikaga; Tomoyuki Okuaki; Marc Van Cauteren; Takamichi Murakami
Journal:  Acta Radiol       Date:  2012-03-15       Impact factor: 1.990

Review 5.  Mapping the future of cardiac MR imaging: case-based review of T1 and T2 mapping techniques.

Authors:  Scott A Hamlin; Travis S Henry; Brent P Little; Stamatios Lerakis; Arthur E Stillman
Journal:  Radiographics       Date:  2014-10       Impact factor: 5.333

6.  Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging.

Authors:  Peter Beddy; Penelope Moyle; Masako Kataoka; Adam K Yamamoto; Ilse Joubert; David Lomas; Robin Crawford; Evis Sala
Journal:  Radiology       Date:  2011-11-23       Impact factor: 11.105

7.  MR Fingerprinting of Adult Brain Tumors: Initial Experience.

Authors:  C Badve; A Yu; S Dastmalchian; M Rogers; D Ma; Y Jiang; S Margevicius; S Pahwa; Z Lu; M Schluchter; J Sunshine; M Griswold; A Sloan; V Gulani
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-29       Impact factor: 3.825

8.  Quantitative T2 mapping of knee cartilage: differentiation of healthy control cartilage and cartilage repair tissue in the knee with unloading--initial results.

Authors:  Tallal C Mamisch; Siegfried Trattnig; Sebastian Quirbach; Stefan Marlovits; Lawrence M White; Goetz H Welsch
Journal:  Radiology       Date:  2010-02-01       Impact factor: 11.105

9.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

10.  Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium.

Authors:  D M Larson; K K Johnson
Journal:  Gynecol Oncol       Date:  1993-12       Impact factor: 5.482

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.